The Medicines & Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (U.K.) issued a temporary authorization for emergency use for the COVID-19 mRNA vaccine (BNT162b2), against COVID-19.
This announcement is the first Emergency Use Authorization (EUA) following a worldwide Phase 3 trial of a vaccine to help fight the pandemic, said Pfizer and BioNTech SE in a press release issued on December 2, 2020.
Read More
